Kindred Biosciences Inc Revenue Growth Rates (KIN), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Kindred Biosciences Inc   (NASDAQ: KIN)
 

KIN's Revenue Growth by Quarter and Year

Kindred Biosciences Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

KIN Revenue (in millions $) FY 2021 FY 2020 FY 2019 FY 2018
4th Quarter December -
3rd Quarter September -
2nd Quarter June 3.54
1st Quarter March 2.40
FY 5.94





KIN Revenue second quarter 2021 Y/Y Growth Comment
Kindred Biosciences Inc reported drop in Revenue in the second quarter 2021 by -91.06% to $ 3.54 millions, from the same quarter in 2020.
This represents worst decline in recent Company history.

Looking into second quarter 2021 results within Major Pharmaceutical Preparations industry 235 other companies have achieved higher Revenue growth. While Kindred Biosciences Inc ' s Revenue meltdown of -91.06% ranks overall at the positon no. 3804 in the second quarter 2021.


KIN Revenue ( Y/Y Growth %) 2021
 2020 2019 2018
4th Quarter December - -32.14 % 5.26 % -
3rd Quarter September - -5.45 % 71.88 % -
2nd Quarter June -91.06 % 3091.13 % - -
1st Quarter March 300 % 15.38 % - -
FY   - 889.67 % 116.24 % -

Financial Statements
Kindred Biosciences Inc 's second quarter 2021 Revenue $ 3.54 millions KIN's Income Statement
Kindred Biosciences Inc 's second quarter 2020 Revenue $ 39.57 millions Quarterly KIN's Income Statement


KIN Revenue (Quarter on Quarter Growth %)

 2021
 2020 2019 2018
4th Quarter December - -8.65 % 27.27 % 107.81 %
3rd Quarter September - -97.37 % -11.29 % -
2nd Quarter June 47.38 % 6495 % 138.46 % -
1st Quarter March 152.63 % -57.14 % -60.9 % -
FY (Year on Year)   - 889.67 % 116.24 % -


Back to KIN Growth rate Comparisons >> Back to KIN Growth rate Comparisons >>


Revenue second quarter 2021 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #236
Healthcare Sector #569
Overall #3804

Revenue Y/Y Growth Statistics
High Average Low
3101.21 % 420.62 % -91.06 %
(Jun 30 2020)   (Jun 30 2021)
Revenue second quarter 2021 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #236
Healthcare Sector #569
Overall #3804
Revenue Y/Y Growth Statistics
High Average Low
3101.21 % 420.62 % -91.06 %
(Jun 30 2020)   (Jun 30 2021)

Revenue by Quarter for the Fiscal Years 2018, 2019, 2020, 2021

Kindred Biosciences Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
6461.69 % 609.12 % -97.36 %
(Jun 30 2020)  


KIN's II. Quarter Q/Q Revenue Comment
Kindred Biosciences Inc achieved in the II. Quarter 2021 below company average Revenue jump of 47.38% quarter on quarter, to $ 3.54 millions.

Within Major Pharmaceutical Preparations industry 75 other companies have achieved higher Revenue quarter on quarter growth. While Kindred Biosciences Inc 's Revenue growth quarter on quarter, overall rank is 527.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #76
Healthcare Sector #135
Overall #527
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #76
Healthcare Sector #135
Overall #527
Revenue Q/Q Growth Statistics
High Average Low
6461.69 % 609.12 % -97.36 %
(Jun 30 2020)  


KIN's II. Quarter Q/Q Revenue Comment
Kindred Biosciences Inc achieved in the II. Quarter 2021 below company average Revenue jump of 47.38% quarter on quarter, to $ 3.54 millions.

Within Major Pharmaceutical Preparations industry 75 other companies have achieved higher Revenue quarter on quarter growth. While Kindred Biosciences Inc 's Revenue growth quarter on quarter, overall rank is 527.


Kindred Biosciences Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2021)		 12 Months Ending
(Mar 31 2021)		 12 Months Ending
(Dec 31 2020)		 12 Months Ending
(Sep 30 2020)		 12 Months Ending
(Jun 30 2020)
Cumulative Revenue 12 Months Ending $ 7.93 $ 43.96 $ 42.16 $ 42.61 $ 42.68
Y / Y Revenue Growth (TTM) -81.43 % 911.88 % 890.7 % 919.23 % 1048.1 %
Year on Year Revenue Growth Overall Ranking # 41 # 36 # 17 # 12 # 43
Seqeuential Revenue Change (TTM) -81.97 % 4.25 % -1.06 % -0.14 % 882.39 %
Seq. Revenue Growth (TTM) Overall Ranking # 47 # 1202 # 1963 # 2017 # 1659


Cumulative Revenue growth Comment
For the 12 months ended Jun 30 2021 Kindred Biosciences Inc reported a sharp drop in Revenue by -81.43% year on year, to $8 millions, compare to the 911.88% growth at Mar 31 2021.

Among companies within the Healthcare sector 19 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 36 to 41.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 10
Healthcare Sector # 20
Overall # 41

Revenue TTM Y/Y Growth Statistics
High Average Low
1048.1 %
 737.7 %
-81.43 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 10
Sector # 21
S&P 500 # 47
Cumulative Revenue growth Comment
For the 12 months ended Jun 30 2021 Kindred Biosciences Inc reported a sharp drop in Revenue by -81.43% year on year, to $8 millions, compare to the 911.88% growth at Mar 31 2021.

Among companies within the Healthcare sector 19 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 36 to 41.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 10
Healthcare Sector # 20
Overall # 41

Revenue TTM Y/Y Growth Statistics
High Average Low
1048.1 %
737.7 %
-81.43 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 10
Sector # 21
S&P 500 # 47




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
KIN's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue sharp drop for the quarter ending Jun 30 2021 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2021
Heron Therapeutics Inc -0.99%$ -0.993 millions
Vaso Corporation-1.28%$ -1.279 millions
Thermogenesis Holdings Inc -1.83%$ -1.829 millions
Cytomx Therapeutics Inc -1.93%$ -1.927 millions
Miromatrix Medical inc -2.78%$ -2.777 millions
Diversicare Healthcare Services Inc -2.90%$ -2.896 millions
Curis Inc -3.14%$ -3.136 millions
Sunlink Health Systems Inc -3.31%$ -3.312 millions
Arvinas Inc -3.54%$ -3.536 millions
Navidea Biopharmaceuticals Inc -3.71%$ -3.709 millions
Emergent Biosolutions Inc -4.38%$ -4.383 millions
Neurocrine Biosciences Inc -4.46%$ -4.464 millions
Infusystem Holdings Inc-4.48%$ -4.481 millions
Rockwell Medical inc -4.77%$ -4.775 millions
Cv Sciences Inc -4.97%$ -4.967 millions
Acorda Therapeutics Inc -5.45%$ -5.452 millions
Cumberland Pharmaceuticals Inc -5.65%$ -5.654 millions
American Cryostem Corporation-6.24%$ -6.238 millions
Elite Pharmaceuticals Inc -6.39%$ -6.393 millions
Hill rom Holdings Inc -6.49%$ -6.489 millions
Pediatrix Medical Group Inc -7.12%$ -7.118 millions
Clovis Oncology inc -7.69%$ -7.689 millions
Lifevantage Corp-7.73%$ -7.733 millions
Wave Life Sciences Ltd -8.29%$ -8.292 millions
Pacific Health Care Organization Inc-8.39%$ -8.391 millions
Kaya Holdings Inc -9.35%$ -9.347 millions
Alerislife Inc -9.76%$ -9.757 millions
Inovio Pharmaceuticals Inc -10.01%$ -10.014 millions
U s Stem Cell Inc -10.62%$ -10.622 millions
Aclaris Therapeutics Inc -10.85%$ -10.850 millions


About Kindred Biosciences Inc Revenue Growth Rates (KIN), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: the company’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.